We’ll contact you with important product updates, including clinical and coverage information. A local Lilly Sales Specialist may also contact you to schedule a meeting.
We’ll contact you with important product updates, including clinical and coverage information. If you have any questions in the meantime, please contact Ask Lilly at 1-800-LillyRx (545-5979).
You are now leaving the www.LARTRUVO.com website.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016